Influenza A/H1N1

Circle Oncodesign Services

Help the development of vaccine and innovative therapies against Influenza A/H1N1


Influenza A/H1N1, commonly known as swine flu, is a subtype of the influenza virus A that causes respiratory illness in humans. Understanding H1N1 and other influenza viruses is critical for the development of new vaccine and innovative therapies.

At Oncodesign Services, we are engaged and committed to help finding therapeutic solutions and innovative treatments against on human infectious diseases, including Influenza A/H1N1, by providing access to facilities and cutting edge equipment for R&D programs. Learn more here.

Preclinical evaluation for Influenza A/H1N1 vaccine and new therapies candidate


Continuous monitoring of influenza viruses is crucial for early detection of new strains and effective vaccine formulation. Studies focus on understanding virus mutations, transmission dynamics, and improving treatment and prevention strategies.

In preclinical evaluations of new influenza vaccine candidates, representative in vitro and in vivo experimental systems are essential to assess specific immune responses. These models help researchers develop vaccines, therapeutics, and other control measures.

At Oncodesign Services, our in vitro laboratories are certified to handle BSL2 and BSL3 pathogens related to influenza A/H1N1. 


We provide typical assays for viral studies on influenza:

  • hemagglutination test
  • colorimetric assay as cytopathogen effects exhibited
  • cell viability
  • antibody neutralization
  • viral-induced cytotoxicity
  • viral load by RT-qPCR (relative value) and digital PCR (absolute value in number of viral copy)
  • compound binding
  • inhibition of infectivity and cytokine expression
  • immufluorescence with HCS imaging (ImageXpress® Pico technology)
  • viral expression by cell imaging
  • viral replication with commercial kit


Hemagglutination Assay – titre of viral stock


HIA – titre of serum : Exemple of calculated titre of HIA Positivity of the 1 32 nd dilution Serum – Titre of HIA 32


With our network of partners, we can also provide in vivo testing until clinical trials to study the efficacy of new therapies against Influenza A/H1N1.

Oncodesign Services can offer integrated drug discovery and preclinical programs (INPACT) for antivirals, from chemistry, screening to in vivo proof of concept. With all the capabilities under the same roof, we can offer fast cycle times.

Other pathogens available at Oncodesign Services in vitro laboratories:


  • SARS-CoV-2 with different variants (G614, alpha, beta, gamma, delta, omicron, BA.5)
  • Arboviruses (Chikungunya, Dengue, Zika…)
  • Human rhinovirus and parainfluenza3
  • Herpes (HSV-1 and -2)
  • Respiratory syncytial virus (RSV)
  • Human immunodeficiency virus (HIV-1 and -2)


Learn more about our Infectious diseases models